Acutus Medical Inc (AFIB)

$0.1704

Market is closed - opens 7 PM, 16 Apr 2024

Insights on Acutus Medical Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 5.28M → -7.53M (in $), with an average decrease of 81.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -13.23M → -33.76M (in $), with an average decrease of 77.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.5% return, outperforming this stock by 106.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.4% return, outperforming this stock by 165.0%

Performance

  • $0.17
    $0.18
    $0.17
    downward going graph

    2.94%

    Downside

    Day's Volatility :10.23%

    Upside

    7.51%

    downward going graph
  • $0.16
    $1.09
    $0.17
    downward going graph

    5.88%

    Downside

    52 Weeks Volatility :85.32%

    Upside

    84.4%

    downward going graph

Returns

PeriodAcutus Medical IncSector (Health Care)Index (Russel 2000)
3 Months
-3.58%
-0.6%
0.0%
6 Months
-71.25%
5.9%
0.0%
1 Year
-74.62%
3.2%
-0.7%
3 Years
-98.64%
14.3%
-21.8%

Highlights

Market Capitalization
5.2M
Book Value
- $0.03
Earnings Per Share (EPS)
-0.41
Wall Street Target Price
0.5
Profit Margin
0.0%
Operating Margin TTM
-288.73%
Return On Assets TTM
-13.8%
Return On Equity TTM
-32.16%
Revenue TTM
7.2M
Revenue Per Share TTM
0.25
Quarterly Revenue Growth YOY
43.7%
Gross Profit TTM
-15.5M
EBITDA
-20.5M
Diluted Eps TTM
-0.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Acutus Medical Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 193.43%

Current $0.17
Target $0.50

Company Financials

FY18Y/Y Change
Revenue
2.2M
-
Net Income
-47.9M
-
Net Profit Margin
-2.2K%
-
FY19Y/Y Change
Revenue
2.8M
↑ 30.93%
Net Income
-119.3M
↑ 149.04%
Net Profit Margin
-4.2K%
↓ 1995.11%
FY20Y/Y Change
Revenue
8.5M
↑ 198.45%
Net Income
-102.0M
↓ 14.52%
Net Profit Margin
-1.2K%
↑ 3002.0%
FY21Y/Y Change
Revenue
17.3M
↑ 103.96%
Net Income
-123.4M
↑ 20.96%
Net Profit Margin
-714.59%
↑ 490.29%
FY22Y/Y Change
Revenue
16.4M
↓ 5.21%
Net Income
-39.6M
↓ 67.89%
Net Profit Margin
-242.11%
↑ 472.48%
FY23Y/Y Change
Revenue
7.2M
↓ 56.22%
Net Income
-81.7M
↑ 106.14%
Net Profit Margin
-1.1K%
↓ 897.8%
Q4 FY22Q/Q Change
Revenue
5.0M
↑ 36.17%
Net Income
15.1M
↓ 174.1%
Net Profit Margin
304.47%
↑ 863.99%
Q1 FY23Q/Q Change
Revenue
4.2M
↓ 15.96%
Net Income
-16.6M
↓ 210.07%
Net Profit Margin
-398.8%
↓ 703.27%
Q2 FY23Q/Q Change
Revenue
5.3M
↑ 26.83%
Net Income
-18.3M
↑ 10.32%
Net Profit Margin
-346.87%
↑ 51.93%
Q3 FY23Q/Q Change
Revenue
5.2M
↓ 0.96%
Net Income
-13.2M
↓ 27.85%
Net Profit Margin
-252.71%
↑ 94.16%
Q4 FY23Q/Q Change
Revenue
-7.5M
↓ 243.8%
Net Income
-33.8M
↑ 155.08%
Net Profit Margin
448.29%
↑ 701.0%
Q1 FY24Q/Q Change
Revenue
-7.5M
↑ 0.0%
Net Income
-33.8M
↑ 0.0%
Net Profit Margin
448.29%
↑ 0.0%
FY18Y/Y Change
Total Assets
25.9M
-
Total Liabilities
157.8M
-
FY19Y/Y Change
Total Assets
105.5M
↑ 306.41%
Total Liabilities
331.3M
↑ 109.97%
FY20Y/Y Change
Total Assets
192.5M
↑ 82.58%
Total Liabilities
66.0M
↓ 80.09%
FY21Y/Y Change
Total Assets
169.8M
↓ 11.81%
Total Liabilities
64.1M
↓ 2.86%
FY22Y/Y Change
Total Assets
133.4M
↓ 21.41%
Total Liabilities
58.4M
↓ 8.81%
FY23Y/Y Change
Total Assets
54.0M
↓ 59.56%
Total Liabilities
54.8M
↓ 6.13%
Q4 FY22Q/Q Change
Total Assets
133.4M
↑ 16.41%
Total Liabilities
58.4M
↑ 2.77%
Q1 FY23Q/Q Change
Total Assets
116.0M
↓ 13.07%
Total Liabilities
55.5M
↓ 4.95%
Q2 FY23Q/Q Change
Total Assets
100.3M
↓ 13.54%
Total Liabilities
56.6M
↑ 1.84%
Q3 FY23Q/Q Change
Total Assets
84.7M
↓ 15.52%
Total Liabilities
53.0M
↓ 6.25%
Q4 FY23Q/Q Change
Total Assets
54.0M
↓ 36.31%
Total Liabilities
54.8M
↑ 3.43%
Q1 FY24Q/Q Change
Total Assets
54.0M
↑ 0.0%
Total Liabilities
54.8M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-33.8M
-
Investing Cash Flow
-4.7M
-
Financing Cash Flow
37.4M
-
FY19Y/Y Change
Operating Cash Flow
-56.0M
↑ 65.74%
Investing Cash Flow
-70.4M
↑ 1385.24%
Financing Cash Flow
126.3M
↑ 237.68%
FY20Y/Y Change
Operating Cash Flow
-85.2M
↑ 52.13%
Investing Cash Flow
-63.8M
↓ 9.38%
Financing Cash Flow
164.4M
↑ 30.15%
FY21Y/Y Change
Operating Cash Flow
-99.7M
↑ 17.04%
Investing Cash Flow
19.1M
↓ 129.87%
Financing Cash Flow
79.6M
↓ 51.61%
FY22Y/Y Change
Operating Cash Flow
-85.0M
↓ 14.7%
Investing Cash Flow
104.8M
↑ 449.41%
Financing Cash Flow
-12.1M
↓ 115.23%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.0M
↓ 45.55%
Investing Cash Flow
12.2M
↑ 108.73%
Financing Cash Flow
-15.0K
↓ 96.72%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.5M
↑ 27.24%
Investing Cash Flow
15.1M
↑ 23.9%
Financing Cash Flow
-213.0K
↑ 1320.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.6M
↓ 11.7%
Investing Cash Flow
15.1M
↑ 0.0%
Financing Cash Flow
-21.0K
↓ 90.14%

Technicals Summary

Sell

Neutral

Buy

Acutus Medical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Acutus Medical Inc
Acutus Medical Inc
-10.16%
-71.25%
-74.62%
-98.64%
-99.34%
Stryker Corporation
Stryker Corporation
-3.4%
29.52%
16.83%
33.17%
80.94%
Boston Scientific Corp.
Boston Scientific Corp.
2.78%
35.87%
31.56%
66.59%
80.03%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.2%
26.67%
7.41%
2.59%
43.13%
Abbott Laboratories
Abbott Laboratories
-5.52%
18.37%
4.39%
-11.97%
40.79%
Medtronic Plc
Medtronic Plc
-4.12%
11.68%
-2.42%
-36.33%
-7.76%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Acutus Medical Inc
Acutus Medical Inc
NA
NA
NA
0.0
-0.32
-0.14
NA
-0.03
Stryker Corporation
Stryker Corporation
41.51
41.51
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
64.16
64.16
1.81
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.25
39.25
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.47
33.47
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
26.14
26.14
1.56
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Acutus Medical Inc
Acutus Medical Inc
Buy
$5.2M
-99.34%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$130.1B
80.94%
41.51
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.9B
80.03%
64.16
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.3B
43.13%
39.25
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.3B
40.79%
33.47
14.27%
Medtronic Plc
Medtronic Plc
Buy
$109.3B
-7.76%
26.14
13.0%

Institutional Holdings

  • Deerfield Management Co

    9.08%

  • Orbimed Advisors, LLC

    9.04%

  • Renaissance Technologies Corp

    1.12%

  • Vanguard Group Inc

    0.98%

  • BlackRock Inc

    0.71%

  • Geode Capital Management, LLC

    0.71%

Corporate Announcements

  • Acutus Medical Inc Earnings

    Acutus Medical Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

world class talent with the mission to reshape ep acutus medical has attracted some of the most respected pioneers and leaders in electrophysiology and cardiac device manufacturing to join our organization and our worldwide network of collaborative partners. the common bond that brings us together is our passion and collective capability to revolutionize a field that has not seen major technological advances in decades. our mission of continual innovation is focused on providing electrophysiologists with the highest quality suite of tools, coupled with outstanding clinical and technical support, to better understand and effectively treat complex arrhythmias. electrophysiology is a high growth market with a clear need for a leap-frog technology to address the unmet need for a scientific, medical evidence-based approach to treating atrial fibrillation, ventricular tachycardia and the other complex arrhythmia's. acutus medical is a full-portfolio solution provider for treating these patie

Organization
Acutus Medical Inc
Employees
230
CEO
Mr. Takeo Mukai
Industry
Distribution Services

Discover More

FAQs